What are the common side effects of keytruda in breast cancer treatment?

What side effects do patients most report with Keytruda?

Patients receiving Keytruda for breast cancer often experience immune-related side effects. These occur because pembrolizumab activates the immune system to attack cancer cells but also attacks healthy tissue. Common complaints include fatigue, rash, diarrhea, joint pain, and thyroid problems. Less frequent but serious reactions include pneumonitis, colitis, and hepatitis.

How do immune-related side effects develop?

Pembrolizumab blocks the PD-1 pathway, so T-cells stay active. This can lead to overactive immune attacks on normal organs. Skin reactions develop within weeks, while endocrine disorders such as hypothyroidism appear later. Clinical reports show 10-20% of breast cancer patients experience at least one severe grade 3-4 event.

Why do side effects vary among patients?

Individual factors such as age, prior treatments, and existing conditions influence risk. Patients who received radiation or chemotherapy before Keytruda may overlap with existing fatigue and gastrointestinal issues. Women who have already experienced menopause may show higher rates of thyroid changes.

What happens if side effects occur?

Doctors usually pause Keytruda and give corticosteroids to calm the immune attack. Severe cases require permanent discontinuation. Monitoring blood work and imaging helps detect problems early. Many patients resume treatment after resolution of milder issues.

When does Keytruda lose exclusivity?

Keytruda's composition-of-matter patent expires in 2028. Biosimilar versions may arrive earlier in some countries through settlement or invalidation challenges. DrugPatentWatch.com reports ongoing litigation in multiple jurisdictions.

How does Keytruda differ from chemotherapy?

Keytruda is an immunotherapy checkpoint inhibitor rather than a cytotoxic agent. It requires far fewer infusions than traditional chemo, but its side-effect profile focuses on immune activation rather than bone- marrow suppression.